Overview

* PDS Biotechnology ( PDSB ) Q3 net loss decreases to $9 mln due to lower operating expenses

* Adjusted EPS for Q3 beats analyst expectations

* Company plans expedited approval for VERSATILE-003 Phase 3 trial

Outlook

* PDS Biotech plans to seek accelerated approval for VERSATILE-003 Phase 3 trial

* Company proposes amendment to use PFS as surrogate primary endpoint

* mOS will remain primary endpoint for full FDA approval

Result Drivers

* Research and development expenses were $4.6 million for the three months ended September 30, 2025, compared to $6.8 million for the three months ended September 30, 2024

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS Beat -$0.19 -$0.21

(3

Analysts

)

Q3 Net -$9 mln

Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for PDS Biotechnology Corp ( PDSB ) is $5.00, about 80.7% above its November 12 closing price of $0.96

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)